ClinicalTrials.gov
public full text
Public Domain
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors#904169
- AZD7325 Multiple Ascending Dose Study#995426
- Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.#966609
- Dose Escalation of IPI-493 in Hematologic Malignancies#895058
- Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC#918192
Record · ID 1047995
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive